Enpr EMA. Enpr-EMA. European Network of Paediatric Research at the European Medicines Agency

Similar documents
How Paediatric Research Networks can help drug development

EMA Technical Anonymisation Group (TAG)

Guidance on the anonymisation of clinical reports for the purpose of publication

ENCePP Work Plan

EU s Innovative Medical Technology and EMA s Measures

Informed consent and multiple application*

Safety Signal - Assessment of responses to Request for Supplementary Information (RSI)

Extension application* assessment timetables

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Andalusian Agency for Health Technology Assessment (AETSA)

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...

ENCePP Work Plan

European Network for Health Technology Assessment (EUnetHTA) Joint Action 3

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

Guidance on the anonymisation of clinical reports for the purpose of publication in accordance with policy 0070

Pre- and post-authorisation regulatory support for SMEs

EMA/EC multi-stakeholder workshop to further improve the implementation of the Paediatric Regulation

Final Minutes of EMA/EUnetHTA meeting

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

THE EUROPEAN COUNCIL OF ACADEMIES OF APPLIED SCIENCES, TECHNOLOGIES AND ENGINEERING

OMCL Network of the Council of Europe GENERAL DOCUMENT

EU Cooperation on Health Technology Assessment

WFEO STANDING COMMITTEE ON ENGINEERING FOR INNOVATIVE TECHNOLOGY (WFEO-CEIT) STRATEGIC PLAN ( )

Towards a 21 st Century Regulator s role EMA Early Access Toolbox

SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry

IEEE Internet Initiative

Mobilisation and Mutual Learning (MML) Action Plans on Societal Challenges

Medical Technology Association of NZ. Proposed European Union/New Zealand Free Trade Agreement. Submission to Ministry of Foreign Affairs & Trade

EMA-HTA workshop Bringing together stakeholders for early dialogue in medicines development

MA/INS/GMP/735037/2014 Annex 1 of the GMP Guidelines on Good Manufacturing Practice - Manufacture of Sterile Medicinal Products

Health Based Exposure Limits (HBEL) and Q&As

"Workshops on key economic issues regarding the. enforcement of IPR in the European Union"

Agenda Industry stakeholder platform on research and development support

Gary Condran Associate Director Bureau of Pharmaceutical Sciences, Therapeutic Product Directorate, HPFB, Health Canada

Stakeholders Acting Together On the ethical impact assessment of Research and Innovation

Submission of comments on Review of the Variations Guidelines (EC 1234/2008)

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

EU Research Integrity Initiative

Medical Education Activities

The New Delhi Communiqué

The General Data Protection Regulation and use of health data: challenges for pharmaceutical regulation

IGDRP Mission, Scope, How it works

December Eucomed HTA Position Paper UK support from ABHI

Finn Børlum Kristensen, MD, PhD Director, EUnetHTA Secretariat Danish Health and Medicines Authority (EUnetHTA Coordinator) Copenhagen, Denmark

28 March Report of the Working Group on Pharmaceuticals and Public Health of the High Level Committee on Health.

Triennial Review of the Medicines and Healthcare Products Regulatory Agency. Call for Evidence

ERAC-SFIC 1353/15 AFG/nj 1 DG G 3 C

Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2017

'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint

The ESF Mission. ESF provides a common platform for its Member Organisations (MOs) in order to:

SHTG primary submission process

EUROPEAN COMMISSION Directorate-General for Communications Networks, Content and Technology CONCEPT NOTE

Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market

Current Status and Challenges of Bilateral/Multilateral Meetings

Reduce cost sharing and fees Include other services. Services: which services are covered? Population: who is covered?

The European Platform of Universities engaged in Energy Research (EPUE) an EUA Initiative

Official Journal of the European Union L 117. Legislation. Legislative acts. Volume May English edition. Contents REGULATIONS

A tool on Privacy Enhancing Technologies (PETs) knowledge management and maturity assessment

Inter-Association Task Force

Annual Benefit-Risk Workshop

The Method Toolbox of TA. PACITA Summer School 2014 Marie Louise Jørgensen, The Danish Board of Technology Foundation

Draft Plan of Action Chair's Text Status 3 May 2008

ECC ALL ABOUT OUR ORGANISATION The Electronic Communications Committee

CAPACITIES. 7FRDP Specific Programme ECTRI INPUT. 14 June REPORT ECTRI number

EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS

EMA experience with the review of digital technology proposals in medicine development programmes

International initiatives in data sharing: OECD, CODATA and GICSI. Yukiko Fukasaku Innovmond Padova 21 September 2007

ADVOCACY WORKING GROUP Work Plan

Highlight report of the 2 nd industry stakeholder platform on research and development support

IV/10. Measures for implementing the Convention on Biological Diversity

NCRIS Capability 5.7: Population Health and Clinical Data Linkage

Interaction btw. the GDPR and Clinical Trials Regulation

Swissmedic, Swiss Agency for Therapeutic Products

EN Official Journal of the European Union L 117/176 REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL.

Driving the Future of Digital Experiences Silvia Boi, Jean Dominique Meunier NEM Executive Board Member

WG/STAIR. Knut Blind, STAIR Chairman

Regulation on medicinal products for paediatric use

NHS SOUTH NORFOLK CLINICAL COMMISSIONING GROUP COMMUNICATIONS AND ENGAGEMENT STRATEGY

EARA Strategic Review

4 TH WEST EURASIA ANNUAL ROADMAP MEETING BAKU, AZERBAIJAN 2-4 APRIL 2013

The UNISDR Global Science & Technology Advisory Group for the implementation of the Sendai Framework for Disaster Risk Reduction UNISDR

WIPO Development Agenda

A New Platform for escience and data research into the European Ecosystem.

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

Invitation to take part in the MEP-Scientist Pairing Scheme 2015

The International Pharmacopoeia Overview

DANUBE INNOVATION PARTNERSHIP

BUILDING CAPACITIES: ENTREPRENEURIAL LEARNING AND SME SKILLS

The 45 Adopted Recommendations under the WIPO Development Agenda

Trafford CCG. CCG authorisation 360 o stakeholder survey report. Version 18 Internal Use Only Version 14 Internal Use Only

Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team

Open Science. challenge and chance for medical librarians in Europe.

Second APEC Ministers' Conference on Regional Science & Technology Cooperation (Seoul, Korea, Nov 13-14, 1996) JOINT COMMUNIQUÉ

MERIL MAPPING OF THE EUROPEAN RESEARCH INFRASTRUCTURE LANDSCAPE

ESF Exploratory Workshop "The future of research in sport participation in the lifespan"

COMMISSION STAFF WORKING DOCUMENT STRATEGY FOR EUROPEAN TECHNOLOGY PLATFORMS: ETP 2020

LSIF Convenor s Summary Report to CTI

Committee on Development and Intellectual Property (CDIP)

Transcription:

Enpr EMA European Network of Paediatric Research at the European Medicines Agency Enpr-EMA European Network of Paediatric Research at the European Medicines Agency An agency of the European Union

Enpr EMA European Network of Paediatric Research at the European Medicines Agency Mission statement Enpr-EMA will facilitate studies to increase the availability of medicines authorised for use in the paediatric population. Aims of the network Enpr-EMA aims to fulfil its mission by: establishing a European paediatric research network of national and European specialist networks, investigators and centres with expertise in performing paediatric clinical trials to foster high-quality, ethical research on the safety and effectiveness of medicines for children; efficient inter-network and stakeholder collaboration, to build up the necessary competences at European Union level, and to avoid unnecessary duplication of studies; raising awareness among healthcare professionals, parents, carers, children and young people of the need and support for paediatric clinical trials; assisting and entering into dialogue with ethics committees on issues relevant to research and clinical trials in children.

Legal background One of the objectives of the Paediatric Regulation (Regulation (EC) No 1901/2006) is to foster high-quality ethical research on medicinal products to be used in children. This should be achieved through efficient inter-network and stakeholder collaboration. To meet this objective, the European Medicines Agency established Enpr-EMA, officially launched and presented to stakeholders in March 2011. Early consultation of Enpr-EMA members is encouraged in the new Commission guideline on paediatric investigation plans (PIPs) to facilitate the development of a PIP. Recognition criteria Enpr-EMA's members are required to fulfil a list of criteria in six categories, namely: research experience and ability; network organisation and processes; scientific competencies and ability to provide expert advice; quality-management; training and educational capacity to build competences; public involvement. Operational structure The operational centre of Enpr-EMA is the Coordinating Group (CG), which is responsible for the network's long- and short-term strategy. The European Medicines Agency provides the

secretariat support, and organises and hosts Enpr-EMA meetings. A workshop open to all stakeholders is held at the Agency once a year. Main tasks of the Coordinating Group Facilitate the pharmaceutical industry's access to paediatric clinical-study centres and experts. Identify new and emerging networks, and invite them to apply for Enpr-EMA membership. Act as a forum for communication. Discuss and resolve operational and scientific issues. Develop common educational tools for children and parents, and encourage their participation in clinical trials. Liaise with the European Medicines Agency's Paediatric Committee (PDCO), which is the scientific committee of the network.

Enpr-EMA overview The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical trials in the paediatric population. Members Enpr-EMA members perform research in children (from newborns to adolescents) in multiple therapeutic areas, and ranging from pharmaco kinetics to pharmacovigilance. A fully searchable database provides easy access to each individual Enpr-EMA network: http://enprema.ema.europa.eu Would you like to join Enpr-EMA? Networks, centres or investigators interested in becoming members of Enpr-EMA are invited to complete a self-assessment form (available on the European Medicines Agency's website) and send it to: enprema@ema.europa.eu

Further information Visit www.ema.europa.eu and click on this banner: Or contact: European Medicines Agency Paediatric Medicines - Enpr-EMA 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 E-mail enprema@ema.europa.eu Send a question www.ema.europa.eu/contact Website www.ema.europa.eu European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged.